References:
C Crescioli et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 2004, 150(4), 591-603. [online]
E Colli et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006, 49(1), 82-86. [online]
A Morelli et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 2007, 67(3), 234-247. [online]
G Penna et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009, 69(5), 480-493. [online]
Chemical Name: (1R,5S,Z)-3-((E)-2-((3aS)-3-((S,E)-6-ethyl-6-hydroxyoct-4-en-2-yl)-3a-methyl-3a,4,5,6-tetrahydro-1H-inden-7(7aH)-ylidene)ethylidene)-5-fluoro-4-methylenecyclohexanol
